Filing Flows

Filing Flows › 8-K events › Cencora

Cencora: results of operations

Form 8-K filed Oct 21, 2026 · items 2.02, 7.01

Mergers and acquisitionsCENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY

What the filing says

CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY Builds on Cencora’s MSO platform by adding complementary capabilities and expanding presence across twelve additional states

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Cencora at a glance

Latest quarterQ3 FY26
Revenue$84.8B
Revenue Y/Y+5%
Operating margin1.3%
IndustryWholesale-Drugs, Proprietaries & Druggists' Sundries

Cencora, Q3 FY26: revenue $84.8B (+5% year over year), operating margin 1.3%. The chart follows the revenue to costs, profit and cash.

Cencora: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.